A Pitfall in Drug Discovery

Total Page:16

File Type:pdf, Size:1020Kb

A Pitfall in Drug Discovery SOCIAL ASPECTS OF DRUG DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION ODILIA OSAKWE, MS, PhD Industrial BioDevelopment Laboratory, UHN-MaRS Centre Toronto Medical Discovery Tower and Ryerson University, Toronto, Canada SYED A. A. RIZVI, MSc, MBA, MS, PhD (Pharm), PhD (Chem), MRSC Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, FL, USA Amsterdam • Boston • Heidelberg • London New York • Oxford • Paris • San Diego San Francisco • Singapore • Sydney • Tokyo Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK Copyright © 2016 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further infor- mation about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Pub- lisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such informa- tion or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility. To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN: 978-0-12-802220-7 For information on all Academic Press publications visit our website at http://store.elsevier.com/ Typeset by Thomson Digital Publisher: Mica Haley Acquisition Editor: Kristine Jones Editorial Project Manager: Molly McLaughlin Production Project Manager: Lucía Pérez Designer: Vicky Pearson To Philomena and Chioma PREFACE A considerable number of textbooks have delivered substantial information on the scientific and technological aspects of drug discovery and devel- opment, but very few have touched upon the social aspects. The idea of writing this book was stimulated by this necessity along with an emergent notion, which grew out of my experience as a lecturer on this subject, in Ryerson University. The Social Aspects of Drug Discovery, Development and Commercialization presents a holistic overview of the entire drug discovery process, as it tran- sitions from inception, to a pill in the hands of the patient. It explains the importance for it to be addressed comprehensively, to include all areas that interact with the society. This will enable a proper understanding of the workings of the pharmaceutical enterprise, from which springs forth the medical products that are supplied to the wide public. This will serve as a knowledge base to streamline ideas and perspectives about how drugs are created and distributed; for a regular citizen, an investor in the pharma- ceutical business, or students or professionals who need to be updated on pharmaceutical affairs. In other words, this information helps the reader in decision making on the proper approach to healthcare and its products; and provides for the scholar or professional, a strong grounding in this subject area. One outstanding characteristic of this textbook is that, it provides defi- nitions and explanations of the relevant background information to serve as a framework for understanding the social aspects, making it a user-friendly resource for a wide range of readers. It details the key participants, rela- tionships, and processes involved in the full drug discovery programs that span the pharmaceutical product lifecycle that are necessary for creating the medical solutions delivered to the public, as represented in the pharmaceuti- cal ecosystems. Analysis of the paths of pharmaceutical innovation is within the context of the pharmaceutical ecosystem. For example, pharmaceuti- cal policy and laws have emanated from extensive debate by a hierarchy of government-appointed groups, agencies, social groups, such as patient representative groups, representatives of charities and consumer associations, pharmaceutical and allied professionals, and other groups from various strata of the healthcare systems who are the voice of command in these decision making activities. Pharmaceutical ecosystems embrace the stakeholders, the xiii xiv Preface processes, and technologies whose cross-interactions strengthen the drug discovery programs. What type of knowledge is gained by the readers of this book? The introductory chapter gives a general overview of the whole pro- cess, which serves as a foundation for the rest of the 13 chapters. Every chapter sequentially builds from the previous and all of which represent a progressive pathway in the discovery of an investigational drug molecule as it morphs into a full drug product that is accessed by the public. This book attempts to answer certain exemplary questions. Chapter 1: What is the origin, meaning, and relevance of the pharmaceutical laws and regulations? Chapter 2: What is the pharmaceutical productivity landscape? Is pharmaceutical innovation sustainable? What is the technological flow, applicability, and effectiveness? What is the economic landscape for emerg- ing pharmaceutical firms? What are the prospects and trend over the years? Chapter 3: What is responsible for hiatus or demise of the drug discovery pipeline in the initial stages of the drug discovery events? What are the re- lationships between the emerging and the big pharmaceutical companies? Chapters 4-6: How is the drug discovery pipeline advancing toward pro- viding the needed medical solutions to diseases, especially the deadly ones? What are the hopes of families that have to grapple with life-threatening diseases? What is new in finding disease pathways and new drug mol- ecules? Chapter 7: The animals chosen for testing of drug candidates, does this decision directly correlate with therapy pursued or are animals over utilized? How do the different species differ in pharmacological response? Chapters 8 and 9: Are drugs manufactured to precision? What is the reason for drug recalls? Chapter 9: Are clinical trials conducted to reflect specific public interests? What are the patients’ rights as participants in clinical tri- als? What are the opportunities and setbacks in multinational clinical trials? Chapter 10: Why are certain drugs more compatible with certain individu- als and the experienced adverse events in only certain individuals? What is the applicability of individualized or precision medicine? Chapter 11: How does patents alter drug accessibility? What are the legal factors that affect patents and emergence of generics? How fast could generics be reached? Chapter 12: How does drug marketing benefit the end user? Chapter 13: What is the flow of drug pricing around the globe? This book could serve as a training tool or reference guide for students and professionals in most of health science and allied disciplines; pharmacy, pharmaceutical sciences, pharmacology, clinical and translational research, medicine, nursing, and more. This also applies to those in pharmaceutical Preface xv law and policy, health policy and management, and pharmacoeconomics. It can also be a useful information base for students and professionals in regulatory affairs, who are expected to be thorough in the knowledge of drug discovery. The text is delivered in a concise, direct, and soft language to stimulate interest and enliven your readership. I would like to extend my personal gratitude to Dr Syed A.A. Rizvi for his valued contribution to this work. Most and foremost, my hearty thanks goes to He who is the pillar of my life and who supplied the knowledge, courage, and strength that carried me throughout this process. Introduction 1 TRENDS IN DRUG DISCOVERY The pharmaceutical industry is of tremendous value to society, mainly be- cause of the active discovery and development of pharmaceuticals, which have increased quality of life through both ameliorating pain and suffering, and the treatment of diseases. Major landmarks in drug discovery that preceded the thalidomide trage- dy in the 1950s have led to a total overhaul of regulatory systems. Extensive federal governance has been deemed necessary to address the unsatisfactory efficacy and safety standards that characterized earlier drug manufactur- ing systems, which underlie
Recommended publications
  • Citing Data Using ACS Style
    Sciences and Technology Library Citing Data using ACS Style ACS Style Guidelines for Citing Data The examples below are suggested formats for citing data such as physical property data or spectra obtained from various types of resources. The ACS Style Guide provides a few examples for citing data but does not include examples of the wide variety of online sources that are available. The purpose of the citation is to provide sufficient detail so that someone else can locate the data. Page numbers may not exist when citing online sources of data and therefore it may be necessary to indicate information like the CAS Registry Number or the entry name so that someone else can locate the exact information that was cited. For more information consult the ACS Style Guide: Effective Communication of Scientific Communication, 3rd edition (Sciences and Technology Library Reference QD 8.5 A25 2006). Citation Examples for Citing Data Web Sites Web sites can be government sites, organization sites, course web sites or personal home pages. Some websites are considered databases and should be cited as a database. See the information on databases listed below. Databases include a reference number or other identifying information along with one or more search options. General Features of Web Sites: accessible on the Internet no page numbers information cited is located at the URL provided – no additional searching is required Where to Find Citation Information: Look at the About Us links, Contact Us links, Copyright link, copyright information at the bottom of the search screen, links with the word Citation or Cite.
    [Show full text]
  • Financial Statements and Trustees' Report 2017
    Royal Society of Chemistry Financial Statements and Trustees’ Report 2017 About us Contents We are the professional body for chemists in the Welcome from our president 1 UK with a global community of more than 50,000 Our strategy: shaping the future of the chemical sciences 2 members in 125 countries, and an internationally Chemistry changes the world 2 renowned publisher of high quality chemical Chemistry is changing 2 science knowledge. We can enable that change 3 As a not-for-profit organisation, we invest our We have a plan to enable that change 3 surplus income to achieve our charitable objectives Champion the chemistry profession 3 in support of the chemical science community Disseminate chemical knowledge 3 and advancing chemistry. We are the largest non- Use our voice for chemistry 3 governmental investor in chemistry education in We will change how we work 3 the UK. Delivering our core roles: successes in 2017 4 We connect our community by holding scientific Champion for the chemistry profession 4 conferences, symposia, workshops and webinars. Set and maintain professional standards 5 We partner globally for the benefit of the chemical Support and bring together practising chemists 6 sciences. We support people teaching and practising Improve and enrich the teaching and learning of chemistry 6 chemistry in schools, colleges, universities and industry. And we are an influential voice for the Provider of high quality chemical science knowledge 8 chemical sciences. Maintain high publishing standards 8 Promote and enable the exchange of ideas 9 Our global community spans hundreds of thousands Facilitate collaboration across disciplines, sectors and borders 9 of scientists, librarians, teachers, students, pupils and Influential voice for the chemical sciences 10 people who love chemistry.
    [Show full text]
  • UC Berkeley UC Berkeley Electronic Theses and Dissertations
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Supercharging methods for improving analysis and detection of proteins by electrospray ionization mass spectrometry Permalink https://escholarship.org/uc/item/93j8p71p Author Going, Catherine Cassou Publication Date 2015 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Supercharging methods for improving analysis and detection of proteins by electrospray ionization mass spectrometry by Catherine Cassou Going A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Chemistry in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Evan R. Williams, chair Professor Kristie A. Boering Professor Robert Glaeser Fall 2015 Supercharging methods for improving analysis and detection of proteins by electrospray ionization mass spectrometry Copyright 2015 by Catherine Cassou Going Abstract Supercharging methods for improving analysis and detection of proteins by electrospray ionization mass spectrometry by Catherine Cassou Going Doctor of Philosophy in Chemistry University of California, Berkeley Professor Evan R. Williams, Chair The characterization of mechanisms, analytical benefits, and applications of two different methods for producing high charge state protein ions in electrospray ionization (ESI) mass spectrometry (MS), or "supercharging", are presented in this dissertation. High charge state protein ions are desirable in tandem MS due to their higher fragmentation efficiency and thus greater amount of sequence information that can be obtained from them. The first supercharging method, supercharging with reagents (typically non-volatile organic molecules), is shown in this work to be able to produce such highly charged protein ions from denaturing solutions that about one in every three residues carries a charge.
    [Show full text]
  • Chemspider – Is This the Future of Linked Chemistry on the Internet?
    ChemSpider – Is This The Future of Linked Chemistry on the Internet? Antony Williams BAGIM, Boston, August 2010 Our dog has fleas It’s not an Advantage… What is the structure of “Advantage”? . Audience Participation Time…. Where would you look? . What would you trust? . Where would you look ONLINE? What is the Structure of Vitamin K? MeSH . A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K What is the Structure of Vitamin K1? Wikipedia What is the Structure of Vitamin K1? CAS’s Common Chemistry PubChem “2-methyl-3-(3,7,11,15-tetramethylhexadec-2- enyl)naphthalene-1,4-dione” . Variants of systematic names on PubChem . 2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethyl . 2-methyl-3-[(E,7S,11R)-3,7,11,15-tetramethyl . 2-methyl-3-[(E,7R,11S)-3,7,11,15-tetramethyl . 2-methyl-3-[(E,7S,11S)-3,7,11,15-tetramethyl . 2-methyl-3-[(E,11S)-3,7,11,15-tetramethyl . 2-methyl-3-[(E)-3,7,11,15-tetramethyl . 2-methyl-3-(3,7,11,15-tetramethyl . 2-methyl-3-[(E)-3,7,11,15-tetramethyl Bioassay Data are Associated… Structures on DailyMed Lack of Stereochemistry Does Stereochemistry Matter? Does one stereocenter matter? .
    [Show full text]
  • One Million Structures and Counting the Journey, the Insights, and the Future of the CSD
    One Million Structures and Counting The journey, the insights, and the future of the CSD Suzanna Ward The Cambridge Crystallographic Data Centre ECM32 – Wednesday 21st August 2019 2 The Cambridge Structural Database (CSD) 1,013,731 ▪ Every published Structures structure An N-heterocycle published produced by a that year ▪ Inc. ASAP & early view chalcogen-bonding ▪ CSD Communications catalyst. Determined Structures at Shandong published ▪ Patents University in China by previously Yao Wang and his ▪ University repositories team. XOPCAJ - The millionth CSD structure. ▪ Every entry enriched and annotated by experts ▪ Discoverability of data and knowledge ▪ Sustainable for over 54 years 3 Inside the CSD Organic ligands Additional data Organic Metal-Organic • Drugs • 10,860 polymorph families 43% 57% • Agrochemicals • 169,218 melting points • At least one transition metal, Pigments • 840,667 crystal colours lanthanide, actinide or any of Al, • Explosives Ga, In, Tl, Ge, Sn, Pb, Sb, Bi, Po • 700,002 crystal shapes • Protein ligands • 23,622 bioactivity details Polymeric: 11% Polymeric: • 9,740 natural source data Not Polymeric Metal-Organic • > 250,000 oxidation states 89% • Metal Organic Frameworks • Models for new catalysts ligand Links/subsets • Porous frameworks for gas s • Drugbank storage • Druglike • Fundamental chemical bonding • MOFs Single Multi ligands • PDB ligands Component Component • PubChem 56% 44% • ChemSpider • Pesticides 4 1965 The sound of music • Film first released in 1965 • Highest grossing film of 1965 • Set in Austria 5 The 1960s Credits: NASA Credits: Thegreenj 6 The vision • Established in 1965 by Olga Kennard • She and J.D. Bernal had a vision that a collective use of data would lead to new knowledge and generate insights J.D.
    [Show full text]
  • An Open Access Knowledge Base for Microbial Natural Products Discovery † † † ‡ § Jeffrey A
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Research Article Cite This: ACS Cent. Sci. 2019, 5, 1824−1833 http://pubs.acs.org/journal/acscii The Natural Products Atlas: An Open Access Knowledge Base for Microbial Natural Products Discovery † † † ‡ § Jeffrey A. van Santen, Gregoire Jacob, Amrit Leen Singh, Victor Aniebok, Marcy J. Balunas, † † ∥ ⊥ # † † Derek Bunsko, Fausto Carnevale Neto, , , Laia Castaño-Espriu, Chen Chang, Trevor N. Clark, ¶ ‡ ◆ # Jessica L. Cleary Little, David A. Delgadillo, Pieter C. Dorrestein, Katherine R. Duncan, † ¶ † † # † Joseph M. Egan, Melissa M. Galey, F.P. Jake Haeckl, Alex Hua, Alison H. Hughes, Dasha Iskakova, ‡ ¶ † † † ‡ Aswad Khadilkar, Jung-Ho Lee, Sanghoon Lee, Nicole LeGrow, Dennis Y. Liu, Jocelyn M. Macho, † ○ ∇ ∇ Catherine S. McCaughey, Marnix H. Medema, Ram P. Neupane, Timothy J. O’Donnell, † ¶ ■ # ○ Jasmine S. Paula, Laura M. Sanchez, Anam F. Shaikh, Sylvia Soldatou, Barbara R. Terlouw, ¶ ⬢ † ○ ‡ ◆ Tuan Anh Tran, , Mercia Valentine, Justin J. J. van der Hooft, Duy A. Vo, Mingxun Wang, † ¶ † Darryl Wilson, Katherine E. Zink, and Roger G. Linington*, † Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada ‡ Department of Chemistry and Biochemistry, University of California, Santa Cruz, California 65064, United States § Division of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Connecticut, Storrs,
    [Show full text]
  • Identification of a Novel Biosynthetic Gene Cluster in Aspergillus Niger
    Journal of Fungi Article Identification of a Novel Biosynthetic Gene Cluster in Aspergillus niger Using Comparative Genomics Gregory Evdokias 1, Cameron Semper 2, Montserrat Mora-Ochomogo 1, Marcos Di Falco 1 , Thi Truc Minh Nguyen 1 , Alexei Savchenko 2, Adrian Tsang 1 and Isabelle Benoit-Gelber 1,* 1 Centre for Structural and Functional Genomics, Department of Biology, Concordia University, 7141 Rue Sherbrooke Ouest, Montréal, QC H4B 1R6, Canada; [email protected] (G.E.); [email protected] (M.M.-O.); [email protected] (M.D.F.); [email protected] (T.T.M.N.); [email protected] (A.T.) 2 Department of Microbiology, Immunology and Infectious Disease, University of Calgary, 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada; [email protected] (C.S.); [email protected] (A.S.) * Correspondence: [email protected] Abstract: Previously, DNA microarrays analysis showed that, in co-culture with Bacillus subtilis, a biosynthetic gene cluster anchored with a nonribosomal peptides synthetase of Aspergillus niger is downregulated. Based on phylogenetic and synteny analyses, we show here that this gene cluster, NRRL3_00036-NRRL3_00042, comprises genes predicted to encode a nonribosomal pep- tides synthetase, a FAD-binding domain-containing protein, an uncharacterized protein, a trans- porter, a cytochrome P450 protein, a NAD(P)-binding domain-containing protein and a transcription factor. We overexpressed the in-cluster transcription factor gene NRRL3_00042. The overexpres- Citation: Evdokias, G.; Semper, C.; sion strain, NRRL3_00042OE, displays reduced growth rate and production of a yellow pigment, Mora-Ochomogo, M.; Di Falco, M.; which by mass spectrometric analysis corresponds to two compounds with masses of 409.1384 and Nguyen, T.T.M.; Savchenko, A.; 425.1331.
    [Show full text]
  • Annual Review 2011
    Annual Review 2011 www.rsc.org Contents 01 Welcome from the President 02 A message from the Chief Executive 03 Supporting a strong membership 07 Leading the global chemistry community 11 Engaging people with chemistry 15 Influencing the future of chemistry 19 Enhancing knowledge 23 Summary of financial information 24 Contacts Professor David Phillips CBE CSci CChem FRSC We championed the cause of chemical sciences with pride and conviction throughout the International Year of Chemistry. ‘‘ Welcome from the President When the United Nations announced that 2011 would be designated the “International Year of Chemistry” (IYC), we knew immediately that the year would bring countless opportunities to promote, expand and evolve both the RSC and the chemical sciences more broadly. We needed to make it a year to remember. I’m delighted to say we rose to the challenge. In a year marked with natural disasters, economic uncertainty and adverse conditions affecting the chemical sciences in ways never seen before, we still led the UK in being perhaps the most active country in the world throughout IYC. Our members did us proud, arranging hundreds of IYC events across the globe. Perhaps most visible was the Global Water Experiment, an international effort to map global water quality using data collected by school pupils. A national media campaign, including an outing on BBC TV’s One Show, led to widespread awareness of the experiment. Dedicated and enthusiastic UK teachers then inspired a sensational number of their pupils to take part, and as a country we contributed more data to the experiment than any other.
    [Show full text]
  • 1 the Re-Emergence of Natural Products for Drug Discovery in The
    The re-emergence of natural products for drug discovery in the genomics era Alan L. Harvey1, RuAngelie Edrada-Ebel2 and Ronald J. Quinn3 1Research and Innovation Support, Dublin City University, Dublin 9, Ireland, and Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 0NR, UK 2Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 0NR, UK 3Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland 4111, Australia Correspondence to A.L.H e-mail: [email protected] 1 Abstract Natural products have been a rich source of compounds for drug discovery. However, their use has diminished in the past two decades in part because of technical barriers to screening natural products in high-throughput assays against molecular targets. Here, we review advances in chemical techniques for the isolation and structural elucidation of natural products that have reduced these technological barriers. We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein–protein interactions. The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery. Introduction There is an increasingly powerful case for revisiting natural products for drug discovery. Historically, natural products from plants and animals were the source of virtually all medicinal preparations, and more recently, natural products have continued to enter clinical trials or to provide leads for compounds that have entered clinical trials, particularly as anticancer and antimicrobial agents1-3.
    [Show full text]
  • Poly(Lactic Acid) Science and Technology: Processing, Properties, Additives and Applications
    Poly(lactic acid) Science and Technology Processing, Properties, Additives and Applications RSC Polymer Chemistry Series Editor-in-Chief: Ben Zhong Tang, The Hong Kong University of Science and Technology, Hong Kong, China Series Editors: Alaa S. Abd-El-Aziz, University of Prince Edward Island, Canada Stephen Craig, Duke University, USA Jianhua Dong, National Natural Science Foundation of China, China Toshio Masuda, Fukui University of Technology, Japan Christoph Weder, University of Fribourg, Switzerland Titles in the Series: 1: Renewable Resources for Functional Polymers and Biomaterials 2: Molecular Design and Applications of Photofunctional Polymers and Materials 3: Functional Polymers for Nanomedicine 4: Fundamentals of Controlled/Living Radical Polymerization 5: Healable Polymer Systems 6: Thiol-X Chemistries in Polymer and Materials Science 7: Natural Rubber Materials: Volume 1: Blends and IPNs 8: Natural Rubber Materials: Volume 2: Composites and Nanocomposites 9: Conjugated Polymers: A Practical Guide to Synthesis 10: Polymeric Materials with Antimicrobial Activity: From Synthesis to Applications 11: Phosphorus-Based Polymers: From Synthesis to Applications 12: Poly(lactic acid) Science and Technology: Processing, Properties, Additives and Applications How to obtain future titles on publication: A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication. For further information please contact: Book Sales Department, Royal Society of Chemistry, Thomas Graham
    [Show full text]
  • JOHNSON-DISSERTATION.Pdf (13.16Mb)
    IN VIVO ANALYSIS OF THE ROLE OF FTSZ1 AND FTSZ2 PROTEINS IN CHLOROPLAST DIVISION IN ARABIDOPSIS THALIANA A Dissertation by CAROL BEATRICE JOHNSON Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 2012 Major Subject: Biology In Vivo Analysis of the Role of FtsZ1 and FtsZ2 Proteins in Chloroplast Division in Arabidopsis thaliana Copyright 2012 Carol Beatrice Johnson IN VIVO ANALYSIS OF THE ROLE OF FTSZ1 AND FTSZ2 PROTEINS IN CHLOROPLAST DIVISON IN ARABIDOPSIS THALIANA A Dissertation by CAROL BEATRICE JOHNSON Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved by: Chair of Committee, Andreas Holzenburg Committee Members, Karl Aufderheide David Stelly Alan Pepper Head of Department, U. Jack McMahan May 2012 Major Subject: Biology iii ABSTRACT In Vivo Analysis of the Role of FtsZ1 and FtsZ2 Proteins in Chloroplast Division in Arabidopsis thaliana. (May 2012) Carol Beatrice Johnson, B.S., Texas Southern University; M.A., Sam Houston State University Chair of Advisory Committee: Dr. Andreas Holzenburg Chloroplasts divide by a constrictive fission process that is regulated by FtsZ proteins. Given the importance of photosynthesis and chloroplasts in general, it is important to understand the mechanisms and molecular biology of chloroplast division. An FtsZ gene is known to be of prokaryotic origin and to have been transferred from a symbiont’s genome to host genome via lateral transfer. Subsequent duplication of the initial FtsZ gene gave rise to the FtsZ1 and FtsZ2 genes and protein families in eukaryotes.
    [Show full text]
  • F2018 Science Medicine Program Review
    Page 1 LAKE SUPERIOR ......,STATE UNIVERSITY Academic Program Review DUE DATE: November 21,2018 The HLC Criteria for Accreditation, specifically Core Component 4.A, require institutions to maintain a "practice of regular program review1ll as one component for ensuring the quality of our educational programs and evaluating our effectiveness in achieving our stated student learning outcomes. For academic units, "Program" means an academic School. School: School of Science and Medicine Degree Programs of the School: • B.S. Biology (indicate which, if any, hold Pre-Medical Concentration specialized programmatic Pre-Veterinary Concentration accreditation) • B.S. Biochemistry Pre-professional - accredited by the American Chemical Society (ACS) • B.S. Chemistry - accredited by the American Chemical Society (ACS) • B.S. Forensic Chemistry - accredited by the American Chemical Society (ACS) • B.S. Medical Laboratory Science - accredited by National Accrediting Agency for Clinical Laboratory Science (NACLS) • A.D. Chemistry • A.D. Chemical Technology Academic Program Review Submission Date: Dean: David Myton, Ph.D. School Chair: Barbara Keller, Ph.D. Names of Faculty Members Barbara Evans, Ph.D. Completing Program Review Report: Jason Garvon, Ph.D. Martha Hutchens, Ph.D. Alexei Iretski, Ph.D. Steven Johnson, Ph.D. Barbara Keller, Ph.D. Stephen Kolomyjec, Ph.D. Jun li, Ph.D. R. Adam Mosey, Ph.D. Thu Nguyen-Mosey, Ph.D. Britton Ranson Olson, Ph.D. I h ttp s://www . hlcommission . or~ Policies/criteria-and-core-comnonents.html PAGE 1 Page 2 Matthew Spencer, Ph.D. Gregory Zimmerman, Ph.D. Guidelines for Completing the Academic Program Review Questions in Part 1 are focused at the School level, and should reflect School-level data, findings, etc.
    [Show full text]